NasdaqCM:SYBX 수익, 비용 및 수입 (USD Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Mar 24	3	-73	13	39
31 Dec 23	3	-57	15	44
30 Sep 23	1	-59	15	47
30 Jun 23	1	-65	16	52
31 Mar 23	1	-66	16	53
31 Dec 22	1	-66	17	52
30 Sep 22	2	-65	17	50
30 Jun 22	2	-63	16	49
31 Mar 22	2	-61	16	48
31 Dec 21	2	-61	15	47
30 Sep 21	1	-60	15	47
30 Jun 21	0	-57	14	44
31 Mar 21	0	-58	14	46
31 Dec 20	1	-59	14	47
30 Sep 20	2	-57	14	47
30 Jun 20	2	-57	15	47
31 Mar 20	2	-54	15	44
31 Dec 19	2	-51	15	42
30 Sep 19	1	-51	15	25
30 Jun 19	3	-48	15	24
31 Mar 19	3	-50	16	25
31 Dec 18	3	-48	16	23
30 Sep 18	3	-48	16	37
30 Jun 18	1	-49	16	36
31 Mar 18	3	-44	14	34
31 Dec 17	2	-40	13	30
30 Sep 17	2	-36	10	28
30 Jun 17	2	-29	9	23
31 Mar 17	0	-24	7	18
31 Dec 16	0	-21	6	15

양질의 수익: SYBX 은(는) 현재 수익성이 없습니다.

이익 마진 증가: SYBX 은(는) 현재 수익성이 없습니다.

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: SYBX 은(는) 수익성이 없으며 지난 5년 동안 연간 5.7% 비율로 손실이 증가했습니다.

성장 가속화: 현재 수익성이 없기 때문에 SYBX 의 지난 1년 동안의 수익 성장을 5년 평균과 비교할 수 없습니다.

수익 대 산업: SYBX 은(는) 수익성이 없어 지난 해 수익 성장을 Biotechs 업계( -14.4% )와 비교하기 어렵습니다.

자기자본 수익률

높은 ROE: SYBX 현재 수익성이 없기 때문에 마이너스 자본 수익률( -549.52% )을 갖습니다.

Synlogic 과거 수익 실적

과거 기준 확인 0/6

주요 정보

최근 과거 실적 업데이트

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

New major risk - Financial position

First quarter 2024 earnings released: US$2.60 loss per share (vs US$3.39 loss in 1Q 2023)

Price target decreased by 96% to US$1.00

Cable Car Capital Discloses its Views on Synlogic

Synlogic, Inc. Announces Departure of Aoife Brennan as Chief Executive Officer

Synlogic, Inc. Announces Departure of Aoife Brennan as President

Synlogic, Inc. Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Companies Like Synlogic (NASDAQ:SYBX) Could Be Quite Risky

Synlogic, Inc. Appoints Chief Financial Officer Changes, Effective December 1, 2023

Consensus revenue estimates increase by 747%

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

New major risk - Shareholder dilution

Consensus EPS estimates upgraded to US$11.03 loss

New major risk - Revenue and earnings growth

Can Synlogic (NASDAQ:SYBX) Afford To Invest In Growth?

Price target decreased by 11% to US$5.00

Synlogic, Inc. Announces Implementation of Reduction in Workforce

Synlogic, Inc. Announces Initiation of Synpheny-3 Global, Pivotal Phase 3 Study Evaluating SYNB1934 for Treatment of Phenylketonuria

Consensus revenue estimates increase by 11%, EPS downgraded

We're A Little Worried About Synlogic's (NASDAQ:SYBX) Cash Burn Rate

Consensus EPS estimates fall by 11%

Synlogic, Inc. Receives Rare Pediatric Disease Designation from FDA for SYNB1934 for Phenylketonuria

Synlogic, Inc. Appoints Dave Hava as Head of Research and Development

Synlogic Receives Non-Compliance Notice From Nasdaq

Synlogic Announces SYNB1353 Achieves Proof of Mechanism for Treatment of Homocystinuria and Provides Business Update

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Consensus forecasts updated

Synlogic Therapeutics: SYNB1934 Advances To Phase 3

Synlogic Announces Positive Top-Line Phase 2 Data for Phenylketonuria (PKU) SYNB1934 Advances to Phase 3

Synlogic gets milestone payment under Roche pact to discover synthetic biotic for bowel disease

Synlogic's metabolic disorder drug gets FDA fast track status

Synlogic, Inc Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks

Synlogic Q2 2022 Earnings Preview

Is Synlogic (NASDAQ:SYBX) In A Good Position To Invest In Growth?

Synlogic, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Synlogic, Inc. Initiates Phase 1 Study of SYNB1353 for the Treatment of Homocystinuria

Synlogic begins dosing in early-stage trial of SYNB1353 for rare metabolic disorder

Synlogic, Inc. Announces Appointment of Brendan St. Amant as Corporate Secretary, Effective July 1, 2022

Consensus forecasts updated

Synlogic, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$8.00

Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs At the Society for Inherited Metabolic Disorders 43Rd Annual Meeting

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Synlogic Announces Appointment of Michael Jensen as Chief Financial Officer

Here's Why We're Watching Synlogic's (NASDAQ:SYBX) Cash Burn Situation

Price target decreased to US$9.00

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Price target increased to US$10.00

Synlogic Presents Data on SYNB8802 for Enteric Hyperoxaluria at American Urological Association (AUA) Annual Meeting

Consensus revenue estimates increase to US$389.7k

Chief Medical Officer Richard Riese has left the company

Synlogic Announces Initiation of Phase 1 Study of SYNB1934 for treatment of Phenylketonuria

Synlogic, Inc. Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Independent Director Chau Khuong has left the company

Synlogic (SYBX) Investor Presentation - Slideshow

Here's Why We Think Synlogic, Inc.'s (NASDAQ:SYBX) CEO Compensation Looks Fair

Synlogic, Inc. Provides Update on its Clinical and Preclinical Programs

Full year 2020 earnings released: US$1.65 loss per share (vs US$1.70 loss in FY 2019)

Price target increased to US$10.00

Synlogic, Inc. to Report Q4, 2020 Results on Mar 25, 2021

Synlogic, Inc Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer

Companies Like Synlogic (NASDAQ:SYBX) Are In A Position To Invest In Growth

Synlogic Appoints Lisa Kelly-Croswell to Its Board of Directors

New 90-day high: US$4.90

Synlogic (NASDAQ:SYBX) Share Prices Have Dropped 67% In The Last Three Years

New 90-day high: US$3.18

Synlogic outlines clinical milestones for 2021

Synlogic, Inc. Announces Advancement of SYNB1891